Sprycel (dasatinib) is an oral targeted anticancer therapy classified as a tyrosine kinase inhibitor (TKI). It used to treat some types of blood cancer, such as Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (Ph+ CML) or acute lymphoblastic leukemia (Ph+ ALL).